Replies to post #133613 on Biotech Values

[mcbio]

And, royalties increase to double, presumably if MNTA finds itself in the lovenox like situation where it can sue to keep others out.

Yeah that's a good point. And, provided they intend to take full advantage of the profit split option on the 4 FoBs after the initial two, entitling them to up to 30% of profits, I'm feeling a little better about the deal as well. Hopefully we get more clarity on this tomorrow. Though I don't think the deal was as good as my expectations, it's better than my initial gut feeling after having read through and thought about the 8-K disclosures a little more.

[ghmm]

Without knowing more details If I were to speculate I think its a so-so deal. I think it reflects that Biosimilars may be more competitive and a harder sell. We don't know what stage of development and which compounds were selected.

Given that FoB are many years out and its looking more and more competitive I would have preferred bigger up front money :-)... But then again the royalties are pretty low as it is so not much room to trade down royalties for more upfront.

[joethdo]

I think it's actually $33 million for the initial two products and option payments totaling $28 million on the additional four products. If all six are included, $61 million total.

In addition there are $391 million in potential payments for various milestones.